Literature DB >> 28053333

Connective tissue disease: Reflections on the EULAR recommendations for the treatment of systemic sclerosis.

Janet E Pope1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28053333     DOI: 10.1038/nrrheum.2016.212

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN: 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  10 in total

1.  Scleroderma treatment differs between experts and general rheumatologists.

Authors:  Janet E Pope; Janine M Ouimet; Adriana Krizova
Journal:  Arthritis Rheum       Date:  2006-02-15

2.  Effect of Macitentan on the Development of New Ischemic Digital Ulcers in Patients With Systemic Sclerosis: DUAL-1 and DUAL-2 Randomized Clinical Trials.

Authors:  Dinesh Khanna; Christopher P Denton; Peter A Merkel; Thomas Krieg; Franck-Olivier Le Brun; Angelina Marr; Kelly Papadakis; Janet Pope; Marco Matucci-Cerinic; Daniel E Furst
Journal:  JAMA       Date:  2016-05-10       Impact factor: 56.272

Review 3.  BSR and BHPR guideline for the treatment of systemic sclerosis.

Authors:  Christopher P Denton; Michael Hughes; Nataliya Gak; Josephine Vila; Maya H Buch; Kuntal Chakravarty; Kim Fligelstone; Luke L Gompels; Bridget Griffiths; Ariane L Herrick; Jay Pang; Louise Parker; Anthony Redmond; Jacob van Laar; Louise Warburton; Voon H Ong
Journal:  Rheumatology (Oxford)       Date:  2016-06-09       Impact factor: 7.580

4.  Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial.

Authors:  Dinesh Khanna; Christopher P Denton; Angelika Jahreis; Jacob M van Laar; Tracy M Frech; Marina E Anderson; Murray Baron; Lorinda Chung; Gerhard Fierlbeck; Santhanam Lakshminarayanan; Yannick Allanore; Janet E Pope; Gabriela Riemekasten; Virginia Steen; Ulf Müller-Ladner; Robert Lafyatis; Giuseppina Stifano; Helen Spotswood; Haiyin Chen-Harris; Sebastian Dziadek; Alyssa Morimoto; Thierry Sornasse; Jeffrey Siegel; Daniel E Furst
Journal:  Lancet       Date:  2016-05-05       Impact factor: 79.321

Review 5.  The 15% rule in scleroderma: the frequency of severe organ complications in systemic sclerosis. A systematic review.

Authors:  Chayawee Muangchan; Murray Baron; Janet Pope
Journal:  J Rheumatol       Date:  2013-07-15       Impact factor: 4.666

6.  A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.

Authors:  Rachel K Hoyles; Ross W Ellis; Jessica Wellsbury; Belinda Lees; Pauline Newlands; Nicole S L Goh; Christopher Roberts; Sujal Desai; Ariane L Herrick; Neil J McHugh; Noeleen M Foley; Stanley B Pearson; Paul Emery; Douglas J Veale; Christopher P Denton; Athol U Wells; Carol M Black; Roland M du Bois
Journal:  Arthritis Rheum       Date:  2006-12

7.  Update of EULAR recommendations for the treatment of systemic sclerosis.

Authors:  Otylia Kowal-Bielecka; Jaap Fransen; Jerome Avouac; Mike Becker; Agnieszka Kulak; Yannick Allanore; Oliver Distler; Philip Clements; Maurizio Cutolo; Laszlo Czirjak; Nemanja Damjanov; Francesco Del Galdo; Christopher P Denton; Jörg H W Distler; Ivan Foeldvari; Kim Figelstone; Marc Frerix; Daniel E Furst; Serena Guiducci; Nicolas Hunzelmann; Dinesh Khanna; Marco Matucci-Cerinic; Ariane L Herrick; Frank van den Hoogen; Jacob M van Laar; Gabriela Riemekasten; Richard Silver; Vanessa Smith; Alberto Sulli; Ingo Tarner; Alan Tyndall; Joep Welling; Frederic Wigley; Gabriele Valentini; Ulrich A Walker; Francesco Zulian; Ulf Müller-Ladner
Journal:  Ann Rheum Dis       Date:  2016-11-09       Impact factor: 19.103

8.  Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers.

Authors:  Anna Abou-Raya; Suzan Abou-Raya; Madihah Helmii
Journal:  J Rheumatol       Date:  2008-08-15       Impact factor: 4.666

9.  Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases.

Authors:  C P Denton; J E Pope; H-H Peter; A Gabrielli; A Boonstra; F H J van den Hoogen; G Riemekasten; S De Vita; A Morganti; M Dölberg; O Berkani; L Guillevin
Journal:  Ann Rheum Dis       Date:  2007-11-30       Impact factor: 19.103

10.  Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.

Authors:  Donald P Tashkin; Michael D Roth; Philip J Clements; Daniel E Furst; Dinesh Khanna; Eric C Kleerup; Jonathan Goldin; Edgar Arriola; Elizabeth R Volkmann; Suzanne Kafaja; Richard Silver; Virginia Steen; Charlie Strange; Robert Wise; Fredrick Wigley; Maureen Mayes; David J Riley; Sabiha Hussain; Shervin Assassi; Vivien M Hsu; Bela Patel; Kristine Phillips; Fernando Martinez; Jeffrey Golden; M Kari Connolly; John Varga; Jane Dematte; Monique E Hinchcliff; Aryeh Fischer; Jeffrey Swigris; Richard Meehan; Arthur Theodore; Robert Simms; Suncica Volkov; Dean E Schraufnagel; Mary Beth Scholand; Tracy Frech; Jerry A Molitor; Kristin Highland; Charles A Read; Marvin J Fritzler; Grace Hyun J Kim; Chi-Hong Tseng; Robert M Elashoff
Journal:  Lancet Respir Med       Date:  2016-07-25       Impact factor: 30.700

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.